Formulary
Alimemazine tartrate: Indications, Dosing, Side Effects and Interactions
Alimemazine tartrate clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Alimemazine tartrate: Indications, Dosing, Side Effects and Interactions
Alimemazine tartrate clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Urticaria,Pruritus**
- **Child** (By Mouth): 12-17 years 10 mg 2-3 times a day, in severe cases doses up to 100 mg per day have been used.
- **Adult** (By Mouth): 10 mg 2-3 times a day, in severe cases doses up to 100 mg per day have been used.
- **Elderly** (By Mouth): 10 mg 1-2 times a day.
**Urticaria, Pruritus for alimemazine tartrate**
- **Child 6 months-1 year (specialist use only)** (By mouth): 250 micrograms/kg 3-4 times a day (max. per dose 2.5 mg).
- **Child 2-4 years** (By mouth): 2.5 mg 3-4 times a day.
- **Child 5-11 years** (By mouth): 5 mg 3-4 times a day.
- **Child 12-17 years** (By mouth): 10 mg 2-3 times a day, in severe cases doses up to 100 mg per day have been used.
**Premedication to anaesthesia for alimemazine tartrate**
- **Child 2-6 years** (By mouth): Up to 2 mg/kg for 1 dose, to be given 1-2 hours before operation.
Cautions
Cardiovascular diseases (due to tachycardia-inducing and hypotensive effects of phenothiazines); elderly (in adults); exposure to sunlight should be avoided during treatment with high doses; pyloroduodenal obstruction; susceptibility to QT interval prolongation; urinary retention; volume depleted patients who are more susceptible to orthostatic hypotension
Contraindications
Children under 2 years except on specialist advice (risk of respiratory depression) (in children); epilepsy; hepatic dysfunction; history of narrow angle glaucoma; hypothyroidism; myasthenia gravis; Parkinson's disease; phaeochromocytoma; prostatic hypertrophy (in adults); renal dysfunction
Side effects
Frequency not known Accommodation disorder; agitation; arrhythmias; atrioventricular block; bile thrombus; constipation; drowsiness; dry mouth; eosinophilia; hepatic disorders; hyperprolactinaemia; insomnia; leucopenia (on prolonged high dose); movement disorders; nasal congestion; parkinsonism; QT interval prolongation; seizure; tardive dyskinesia (more common after long term high doses); urinary retention; ventricular fibrillation (increased risk with hypokalaemia and cardiac disease); ventricular tachycardia (increased risk with hypokalaemia and cardiac disease) Side-effects, further information Drowsiness may diminish after a few days. Children and elderly patients are more susceptible to side-effects.
Interactions
**Other interactions (6):**
- The sedative effects of phenothiazines may be intensified (additively) by alcohol (see section 4.4), anxiolytics and hypnotics, opiates, barbiturates and other sedatives.
- There may be increased antimuscarinic and sedative effects of phenothiazines with tricyclic antidepressants and MAOI's (including moclobemide).
- The use of antimuscarinics will increase the risk of antimuscarinic side effects when used in conjunction with antihistamines.
- These include amfetamine, levodopa, clonidine, guanethidine and adrenaline.
- Some drugs interfere with absorption of phenothiazines: antacids, anti-Parkinson and lithium.
- Increases or decreases in the plasma concentrations of a number of drugs, eg propranolol, phenobarbital have been observed but were not of clinical significance.
Pregnancy
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.
Breast feeding
Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.
Hepatic impairment
Manufacturer advises avoid-no information available.
Renal impairment
Avoid. M
Medicinal forms
Solution,Tablet,Solution
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Alimemazine tartrate in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

